Last Updated: February, 2026
Trusted by 200+ Clients
Compare & Choose the Right Report Version for You
How to Order Your Report?
The report provides a detailed analysis essential for establishing a tositumomab production plant. It encompasses all critical aspects necessary for tositumomab production, including the cost of tositumomab production, tositumomab plant cost, tositumomab production costs, and the overall tositumomab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a tositumomab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Tositumomab is a targeted cancer treatment made from a monoclonal antibody attached to radioactive iodine-131. It seeks out and destroys CD20-positive B-cells responsible for non-Hodgkin lymphoma (NHL), which is a common blood cancer affecting the lymph system. It is made for patients with relapsed or refractory low-grade, follicular, or transformed NHL who no longer respond to standard therapies like rituximab. It delivers radiation directly to tumour cells to shrink them while limiting damage to healthy tissues through its two-step dosing. It has overall response rates around two-thirds of patients and complete remissions in up to a third or more, especially in rituximab-failures.
The market for tositumomab is driven by its FDA approval for relapsed or refractory CD20-positive low-grade, follicular, or transformed NHL. The clinical efficacy shows high response rates in rituximab-failures, and niche demand for targeted radioimmunotherapy in patients exhausted by chemotherapy like CHOP or rituximab, which contributes to its market growth.
The competition from more convenient regimens like CHOP plus rituximab and its superiority over these standards in frontline follicular NHL support its demand. The high treatment costs per course, and complex logistics requiring specialised radiopharmaceutical handling facilities, trained nuclear medicine personnel, and patient isolation protocols influence industrial tositumomab procurement.
According to the tositumomab production plant project report, the key raw materials used in the production of tositumomab include Murine B-cells, myeloma cells, CD20 antigen, and serum-free culture media.
The extensive tositumomab production cost report consists of the following major industrial production process:
Tositumomab is a murine IgG2a lambda monoclonal antibody targeting CD20 that appears as a sterile, pyrogen-free, clear to opalescent, colourless to slightly yellow, preservative-free liquid concentrate. It has a molecular weight of 150 kDa with a molecular formula of C6416H9874N1688O1987S44. It has an isoelectric point of 8.68 with a hydrophobicity of -0.4144. It has a melting point of around 61 °C. It is formulated with 100 mg/mL maltose, 8.5 mg/mL sodium chloride, 1 mg/mL phosphate, and 1 mg/mL potassium hydroxide at pH ~7.2. It is covalently linked to iodine-131 (I-131) for radioimmunotherapy, exhibiting clearance of 68.2 mg/hr in NHL patients via opsonisation or human anti-murine antibody responses.
Tositumomab Production Cost Report
Choose What's Right for You
Pay Via
| Particulars | Details |
|---|---|
| Product Name | Tositumomab |
| Scope | Production Process: Process Flow, Material Flow, Material Balance Raw Material and Product Specifications: Raw Material Consumption, Product and Co-product Generation Land and Site Cost: Offsites/Civil Works, Equipment Cost, Auxiliary Equipment Costs, Contingency, Engineering and Consulting Charges, Working Capital Variable Cost: Raw Material, Utilities, Other Variable Costs Fixed Cost: Labor Requirements and Wages, Overhead Expenses, Maintenance Charges, Other Fixed Costs Financing Costs: Interest on Working Capital, Interest on Loans Other Costs: Depreciation Charges, General Sales and Admin Cost |
| Currency | US$ (Data can also be provided in the local currency) |
| Pricing and Purchase Options | Basic: US$ 2499 Premium: US$ 3499 Enterprise: US$ 4799 |
| Customization Scope | The report can be customized as per the requirement of the customer |
| Post-Sale Analysts Report | 10-12 weeks of post-purchase analyst support after report delivery for any queries from the deliverable |
| Delivery Format | PDF and Excel format through email (editable version in PPT/Word format of the report can be also provided on special request) |
At Procurement Resource, we not only focus on optimizing the should cost of production for tositumomab but also provide our clients with extensive intel and rigorous information on every aspect of the production process. By utilizing a comprehensive cost model, we help you break down expenses related to raw materials, labor, and technology, offering clear pathways to savings. We also assist in evaluating the capital expenditure (CAPEX) and operating expenses (OPEX), which are often measured as cost per unit of production, such as USD/MT, ensuring that your financial planning is aligned with industry benchmarks.
We offer valuable insights on the top technology providers, in-depth supplier database, and best manufacturers, helping you make informed decisions to improve efficiency. Additionally, we design the most feasible layout for your production needs, ensuring the entire process runs smoothly. By minimizing the cash cost of production, we ensure that you stay competitive while securing long-term profitability in the growing tositumomab market. Partnering with Procurement Resource guarantees that every aspect of your production is cost-efficient, advanced, and tailored to your specific requirements.
Lead - Social & Development Research
Delivering procurement intelligence and supply chain analytics across healthcare, FMCG, and chemicals sectors, with expertise in cost modeling, vendor mapping, and spend optimization to support data-driven sourcing decisions and procurement outcomes.
Need more help?
Still Need Help?
